# US 2026/0242494 A1 · Antibody combination specifically binding to trail or fasl, and bispecific antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242494 A1
- Document ID: US20260242494A1
- Status: Published application
- Kind: A1
- Application number: 19/122,572
- Filed: 2023-10-12
- Published: 2026-08-20
- Earliest claimed: 2022-10-20
- Assignees: Beijing Solobio Genetechnology Company Ltd.
- Applicants: Beijing Solobio Genetechnology Co., Ltd.
- Inventors: Guangfei WANG; Zhong LI; Ping LI
- Web page: https://patentgrep.com/patent/US20260242494A1

## CPC

- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61P 35/00: Antineoplastic agents
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/526: CH3 domain
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/66: comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An antibody specifically binding to TRAIL, a bispecific antibody specifically binding to TRAIL and FasL, and a pharmaceutical composition comprising the antibody specifically binding to TRAIL and an antibody and/or bispecific antibody specifically binding to FasL, and a preparation method therefor and a use thereof.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment specifically binding to TRAIL, comprising:
a VH, wherein the VH comprises
an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1,
an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and
an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and
a VL, wherein the VL comprises
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7,
an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and
an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The isolated antibody or antigen-binding fragment specifically binding to TRAIL of claim 1, comprising:
(i) a VH comprising the amino acid sequence of SEQ ID NO: 13, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 13; and a VL comprising the amino acid sequence of SEQ ID NO: 22, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 22;
(ii) a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 23, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 23;
(iii) a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 24, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 24;
(iv) a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 25, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 25;
(v) a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 26, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 26; or
(vi) a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 27, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 27.

### Claim at position 4

4-11. (canceled)

### Claim 12 (depends on 1)

A bispecific antibody, comprising a first antigen-binding domain specifically binding to TRAIL of claim 1, and a second antigen-binding domain specifically binding to FasL; and/or,
wherein the first antigen-binding domain comprises:
(i) a VH comprising the amino acid sequence of any one of SEQ ID NOs: 13 and 33, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 13 and 33; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 22 and 41, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 22 and 41;
(ii) a VH comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 23 and 42, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 23 and 42;
(iii) a VH comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 24 and 43, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 24 and 43; or
(iv) a VH comprising the amino acid sequence of SEQ ID NO: 164, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 164; and a VL comprising the amino acid sequence of SEQ ID NO: 168, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 168.

### Claim at position 6

13-14. (canceled)

### Claim 15 (depends on 12)

The bispecific antibody of claim 12, wherein the second antigen-binding domain comprises:
(i) a VH, wherein the VH comprises
an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and
a VL, wherein the VL comprises
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61;
(ii) a VH, wherein the VH comprises
an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and
a VL, wherein the VL comprises
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; or
(iii) a VH, wherein the VH comprises
an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and
a VL, wherein the VL comprises
an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 162, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; and/or,
wherein the second antigen-binding domain comprises:
(i) a VH comprising the amino acid sequence of any one of SEQ ID NOs: 63 and 80, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 63 and 80; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 73 and 89, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 73 and 89;
(ii) a VH comprising the amino acid sequence of any one of SEQ ID NOs: 64 and 81, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 64 and 81; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 74 and 90, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 74 and 90;
(iii) a VH comprising the amino acid sequence of any one of SEQ ID NOs: 66 and 82, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 66 and 82; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 76 and 92, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 76 and 92;
(iv) a VH comprising the amino acid sequence of any one of SEQ ID NOs: 70 and 86, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 70 and 86; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 78 and 94, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 78 and 94;
(v) a VH comprising the amino acid sequence of any one of SEQ ID NOs: 69 and 85, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 69 and 85; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 79 and 95, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 79 and 95;
(vi) a VH comprising the amino acid sequence of SEQ ID NO: 163, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 163; and a VL comprising the amino acid sequence of SEQ ID NO: 167, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 167; or
(vii) a VH comprising the amino acid sequence of SEQ ID NO: 165, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 165; and a VL comprising the amino acid sequence of SEQ ID NO: 169, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 169.

### Claim 16

(canceled)

### Claim 17 (depends on 12)

The bispecific antibody of claim 12,
a) wherein the first antigen-binding domain comprises: a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11;
and wherein the second antigen-binding domain comprises: a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61; or
b) wherein the first antigen-binding domain comprises: a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11;
and wherein the second antigen-binding domain comprises: a VH comprising
an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56; and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.

### Claim 18 (depends on 17)

The bispecific antibody of claim 17,
a) wherein the first antigen-binding domain comprises: a VH comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 23 and 42, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 23 and 42;
and wherein the second antigen-binding domain comprises: a VH comprising the amino acid sequence of any one of SEQ ID NOs: 64 and 81, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 64 and 81; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 74 and 90, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 74 and 90;
b) wherein the first antigen-binding domain comprises: a VH comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 24 and 43, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 24 and 43;
and wherein the second antigen-binding domain comprises: a VH comprising the amino acid sequence of any one of SEQ ID NOs: 64 and 81, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 64 and 81; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 74 and 90, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 74 and 90;
c) wherein the first antigen-binding domain comprises: a VH comprising the amino acid sequence of SEQ ID NO: 164, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 164;
and a VL comprising the amino acid sequence of SEQ ID NO: 168, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 168;
and wherein the second antigen-binding domain comprises: a VH comprising the amino acid sequence of SEQ ID NO: 163, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 163; and a VL comprising the amino acid sequence of SEQ ID NO: 167, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 167; or
d) wherein the first antigen-binding domain comprises: a VH comprising the amino acid sequence of any one of SEQ ID NOs: 14 and 34, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 14 and 34; and a VL comprising the amino acid sequence of any one of SEQ ID NOs: 23 and 42, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 23 and 42;
and wherein the second antigen-binding domain comprises: a VH comprising the amino acid sequence of SEQ ID NO:163, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 163; and a VL comprising the amino acid sequence of SEQ ID NO: 167, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 167.

### Claim 19 (depends on 12)

The bispecific antibody of claim 12, which comprises an Fc region, wherein
(i) the Fc region is selected from the group consisting of an Fc region of an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD; and/or
(ii) the Fc region comprises a variant Fc region; and/or
(iii) the variant Fc region comprises a substitution at one or more of positions 228, 239, 282, 289, 297, 312, 324, 330, 335, 337, 339, 356, 359, 361, 383, 384, 398, 400, 440, 422, and 442, as numbered by the EU index; and/or
(iv) the Fc region is aglycosylated; or
(v) the Fc region is deglycosylated; or
(vi) the Fc region has reduced fucosylation or is afucosylated.

### Claim at position 12

20-24. (canceled)

### Claim 25 (depends on 12)

The bispecific antibody of claim 12, wherein the bispecific antibody has a format selected from the group consisting of DVD-IgG, Bs4Ab, Hetero H, CrossMab, IgG-(scFv)2, and scFv-Fab IgG.

### Claim 26 (depends on 25)

The bispecific antibody of claim 25, comprising four polypeptide chains selected from (i) and (ii):
(i) wherein two of the polypeptide chains comprise VH1-L-VH2-CH1 structure from the N-terminal to the C-terminal, wherein VH1 is a heavy chain variable domain specifically binding to TRAIL, VH2 is a heavy chain variable domain specifically binding to FasL; L is a linker; CH1 is a heavy chain constant domain 1; wherein the polypeptide chain further comprises Fc that comprises CH2 and CH3 domains; and
the other two of the polypeptide chains comprise the structure of VL1-L-VL2-CL, wherein VL1 is a light chain variable domain specifically binding to TRAIL;
VL2 is a light chain variable domain specifically binding to FasL; L is a linker;
CL is a light chain constant domain; or
(ii) wherein two of the polypeptide chains comprise VH1-L-VH2-CH1 structure from the N-terminal to the C-terminal, wherein VH1 is a heavy chain variable domain specifically binding to FasL, VH2 is a heavy chain variable domain specifically binding to TRAIL; L is a linker; CH1 is a heavy chain constant domain 1; wherein the polypeptide chain further comprises Fc that comprises CH2 and CH3 domains; and
the other two of the polypeptide chains comprise the structure of VL1-L-VL2-CL, wherein VL1 is a light chain variable domain specifically binding to FasL;
VL2 is a light chain variable domain specifically binding to TRAIL; L is a linker;
CL is a light chain constant domain.

### Claim 27

(canceled)

### Claim 28 (depends on 26)

The bispecific antibody of claim 26, wherein the bispecific antibody comprises:
a) the amino acid sequence of SEQ ID NO: 104, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 104; and/or
the amino acid sequence of SEQ ID NO: 105, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 105;
b) the amino acid sequence of SEQ ID NO: 104, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 104; and/or
the amino acid sequence of SEQ ID NO: 106, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 106;
c) the amino acid sequence of SEQ ID NO: 107, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 107; and/or
the amino acid sequence of SEQ ID NO: 108, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 108; or
d) the amino acid sequence of SEQ ID NO: 107, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 107; and/or
the amino acid sequence of SEQ ID NO: 109, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 109.

### Claim 29 (depends on 26)

The bispecific antibody of claim 26, wherein the bispecific antibody comprises:
a) the amino acid sequence of SEQ ID NO: 131, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 131; and/or
the amino acid sequence of SEQ ID NO: 105, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 105;
b) the amino acid sequence of SEQ ID NO: 131, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 131; and/or
the amino acid sequence of SEQ ID NO: 106, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 106;
c) the amino acid sequence of SEQ ID NO: 132, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 132; and/or
the amino acid sequence of SEQ ID NO: 108, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 108; or
d) the amino acid sequence of SEQ ID NO: 132, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 132; and/or
the amino acid sequence of SEQ ID NO: 109, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 109.

### Claim 30 (depends on 25)

The bispecific antibody of claim 25, comprising four polypeptide chains selected from (i) and (ii):
(i) wherein two of the polypeptide chains comprise VH1-CH1-L1-VH2-L3-VL2 or VH1-CH1-L1-VL2-L3-VH2 structure from the N-terminal to the C-terminal, wherein VH1 is a heavy chain variable domain specifically binding to TRAIL;
VH2 is a heavy chain variable domain specifically binding to FasL, VL2 is a light chain variable domain specifically binding to FasL; L1 and L3 are the linker; CH1 is a heavy chain constant domain 1; wherein the polypeptide chain further comprises Fc that comprises CH2 and CH3 domains; and
the other two of the polypeptide chains comprise VL1-CL structure from the N-terminal to the C-terminal, wherein VL1 is a light chain variable domain specifically binding to TRAIL, CL is a light chain constant domain; or
(ii) wherein two of the polypeptide chains comprise VH1-CH1-L1-VH2-L3-VL2 or VH1-CH1-L1-VL2-L3-VH2 structure from the N-terminal to the C-terminal, wherein VH1 is a heavy chain variable domain specifically binding to FasL;
VH2 is a heavy chain variable domain specifically binding to TRAIL, VL2 is a light chain variable domain specifically binding to TRAIL; L1 and L3 are a linker; CH1 is a heavy chain constant domain 1; wherein the polypeptide chain further comprises Fc that comprises CH2 and CH3 domains; and
the other two of the polypeptide chains comprise VL1-CL structure from the N-terminal to the C-terminal, wherein VL1 is a light chain variable domain specifically binding to FasL, CL is a light chain constant domain.

### Claim 31

(canceled)

### Claim 32 (depends on 30)

The bispecific antibody of claim 30, wherein the bispecific antibody comprises:
a) the amino acid sequence of SEQ ID NO: 116, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 116; and/or the amino acid sequence of SEQ ID NO: 119, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119;
b) the amino acid sequence of SEQ ID NO: 117, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 117; and/or the amino acid sequence of SEQ ID NO: 119, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119;
c) the amino acid sequence of SEQ ID NO: 118, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 118; and/or the amino acid sequence of SEQ ID NO: 119, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119;
d) the amino acid sequence of SEQ ID NO: 120, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 120; and/or the amino acid sequence of SEQ ID NO: 121, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 121;
e) the amino acid sequence of SEQ ID NO: 120, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 120; and/or the amino acid sequence of SEQ ID NO: 122, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 122; or
f) the amino acid sequence of SEQ ID NO: 171, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 171; and/or the amino acid sequence of SEQ ID NO: 173, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 173.

### Claim 33 (depends on 30)

The bispecific antibody of claim 30, wherein the bispecific antibody comprises:
a) the amino acid sequence of SEQ ID NO: 138, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 138; and/or the amino acid sequence of SEQ ID NO: 119, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119;
b) the amino acid sequence of SEQ ID NO: 139, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 139; and/or the amino acid sequence of SEQ ID NO: 119, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119;
c) the amino acid sequence of SEQ ID NO: 140, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 140; and/or the amino acid sequence of SEQ ID NO: 119, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 119;
d) the amino acid sequence of SEQ ID NO: 141, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 141; and/or the amino acid sequence of SEQ ID NO: 121, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 121;
e) the amino acid sequence of SEQ ID NO: 141, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 141; and/or the amino acid sequence of SEQ ID NO: 122, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 122;
f) the amino acid sequence of SEQ ID NO: 175, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 175; and/or the amino acid sequence of SEQ ID NO: 173, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 173;
g) the amino acid sequence of SEQ ID NO: 193, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 193; and/or the amino acid sequence of SEQ ID NO: 177, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 177;
h) the amino acid sequence of SEQ ID NO: 194, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 194; and/or the amino acid sequence of SEQ ID NO: 178, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 178;
i) the amino acid sequence of SEQ ID NO: 195, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 195; and/or the amino acid sequence of SEQ ID NO: 179, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 179;
j) the amino acid sequence of SEQ ID NO: 196, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 196; and/or the amino acid sequence of SEQ ID NO: 180, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 180;
k) the amino acid sequence of SEQ ID NO: 197, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 197; and/or the amino acid sequence of SEQ ID NO: 181, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 181;
l) the amino acid sequence of SEQ ID NO: 198, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 198; and/or the amino acid sequence of SEQ ID NO: 182, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 182;
m) the amino acid sequence of SEQ ID NO: 199, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 199; and/or the amino acid sequence of SEQ ID NO: 183 or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 183; or
n) the amino acid sequence of SEQ ID NO: 200, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 200; and/or the amino acid sequence of SEQ ID NO: 184, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 184.

### Claim at position 22

34-41. (canceled)

### Claim 42 (depends on 12)

A pharmaceutical composition comprising the bispecific antibody of claim 12 and a pharmaceutically acceptable carrier or excipient.

### Claim 43

(canceled)

### Claim 44 (depends on 1)

A pharmaceutical composition, comprising the antibody or antigen-binding fragment specifically binding to TRAIL of claim 1 and an antibody or antigen-binding fragment specifically binding to FasL, and/or,
wherein the antibody or antigen-binding fragment specifically binding to TRAIL comprises:
(i) a VH comprising the amino acid sequence of SEQ ID NO: 13, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 13; and a VL comprising the amino acid sequence of SEQ ID NO: 22, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 22;
(ii) a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 23, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 23;
(iii) a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 24, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 24;
(iv) a VH comprising the amino acid sequence of SEQ ID NO: 15, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 15; and a VL comprising the amino acid sequence of SEQ ID NO: 28, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 28;
(v) a VH comprising the amino acid sequence of SEQ ID NO: 20, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 30, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 30; or
(vi) a VH comprising the amino acid sequence of SEQ ID NO: 16, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 31, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 31.

### Claim at position 26

45-46. (canceled)

### Claim 47 (depends on 44)

The pharmaceutical composition of claim 44, wherein the antibody or antigen-binding fragment specifically binding to FasL comprises:
a) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55; and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61; or
b) a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62; and/or,
wherein the antibody or antigen-binding fragment specifically binding to FasL comprises:
(i) a VH comprising the amino acid sequence of SEQ ID NO: 63, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:63; and a VL comprising the amino acid sequence of SEQ ID NO: 73, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 73;
(ii) a VH comprising the amino acid sequence of SEQ ID NO: 64, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:64; and a VL comprising the amino acid sequence of SEQ ID NO: 74, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74;
(iii) a VH comprising the amino acid sequence of SEQ ID NO:66, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 66; and a VL comprising the amino acid sequence of SEQ ID NO: 76, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 76;
(iv) VH comprising the amino acid sequence of SEQ ID NO: 70, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 70; and a VL comprising the amino acid sequence of SEQ ID NO: 78, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 78; or
(vi) a VH comprising the amino acid sequence of SEQ ID NO: 69, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 69; and a VL comprising the amino acid sequence of SEQ ID NO: 79, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 79.

### Claim at position 28

48-51. (canceled)

### Claim 52 (depends on 44)

The pharmaceutical composition of claim 44,
a) wherein the antibody or antigen-binding fragment specifically binding to TRAIL comprises a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11;
and wherein the antibody or antigen-binding fragment specifically binding to FasL comprises a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 51, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 53, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 55;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 57, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 59, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 61;
or
b) wherein the antibody or antigen-binding fragment specifically binding to TRAIL comprises a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 5;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 7, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11;
and wherein the antibody or antigen-binding fragment specifically binding to FasL comprises a VH comprising an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 52, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 54, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 56;
and a VL comprising an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 58, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 60, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 62.

### Claim 53 (depends on 44)

The pharmaceutical composition of claim 44,
a) wherein the antibody or antigen-binding fragment specifically binding to TRAIL comprises a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 23, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 23;
and wherein the antibody or antigen-binding fragment specifically binding to FasL comprises a VH comprising the amino acid sequence of SEQ ID NO: 64, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:64; and a VL comprising the amino acid sequence of SEQ ID NO: 74, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74; or
b) wherein the antibody or antigen-binding fragment specifically binding to TRAIL comprises a VH comprising the amino acid sequence of SEQ ID NO: 14, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 24, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 24; and wherein the antibody or antigen-binding fragment specifically binding to FasL comprises: a VH comprising the amino acid sequence of SEQ ID NO: 64, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO:64; and a VL comprising the amino acid sequence of SEQ ID NO: 74, or a variant thereof having at least about 80% sequence identity to the amino acid sequence of SEQ ID NO: 74.

### Claim at position 31

54-56. (canceled)
